Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

The New Landscape of Checkpoint Inhibitors in China

Chien-Shing Chen, MD PhD

Blood (2018) 132 (Supplement 1): 5855.

https://doi.org/10.1182/blood-2018-99-111666

Published: 2018

Journal Articles

Novel AML-Associated Loss of Function Mutations in the B55 Alpha Subunit of PP2A Are Associated with Increased Phosphorylation and Activation of AKT and Enhanced Sensitivity to AKT Inhibitor Induced Cell Growth Arrest

Geoffrey P. Shouse, MD PhD, Rosalia de Necochea-Campion, MS, Saied Mirshahidi, PhD, Xuan Liu, MD PhD, Chien-Shing Chen, MD PhD

Blood (2014) 124 (21): 2206.

https://doi.org/10.1182/blood.V124.21.2206.2206

Published: 2014

Journal Articles

High Transcription Levels Of S100A8 and S100A9 In Acute Myeloid Leukemia Are Predictors For Poor Overall Survival

Shao-yan Hu, MD, PhD, Ming-ying Zhang, Shui-yan Wu, Dong Wu, Neetika Ashwani, Jian Pan, Ph.D., Hai-long He, Jian-nong Cen, MD, Zi-Xing Chen, MD, Chien-Shing Chen, MD, PhD

Blood (2013) 122 (21): 2610.

https://doi.org/10.1182/blood.V122.21.2610.2610

Published: 2013

Journal Articles

IGFBP7 Gene Promoting Cell Proliferation in Acute Myeloid Leukemia Through Activation of AKT3 and CCND1

Shaoyan Hu, MD, PhD, Shui-yan Wu, MD, Jian-nong Cen, MD, Jian Pan, Ph.D., Xiaofei Qi, Ph.D., Zixing Chen, MD, Ph.D., Xing Feng, MD, Ph.D., Chien-Shing Chen, MD, PhD

Blood (2012) 120 (21): 1447.

https://doi.org/10.1182/blood.V120.21.1447.1447

Published: 2012

Journal Articles

C3aR1 Contributed to Acute Myeloid Leukemia Acquired Resistance to ABT-737 and Involved In the Process of AML

Shaoyan Hu, MD, PhD, Saied Mirshahidi, Ph.D., Chong-Lei Bi, B.S., Wee-Joo Chng, MRCP, MRCPath, Heng-Wei Hsu, B.S., Shui-yan Wu, Jian Pan, Jian-nong Cen, Chien-Shing Chen, MD, PhD

Blood (2011) 118 (21): 1435.

https://doi.org/10.1182/blood.V118.21.1435.1435

Published: 2011

Journal Articles

Bortezomib In Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin Followed by Rituximab Maintenance In Patients with Relapsed or Refractory Follicular Lymphoma: Results of a Phase 2 Study.

Michael Craig, MD, Wahid T Hanna, MD, Fernando Cabanillas, MD, Chien-Shing Chen, MD, PhD, Sudha Parasuraman, MD, Rachel Neuwirth, MS, Owen A. O'Connor, MD, PhD

Blood (2010) 116 (21): 2798.

https://doi.org/10.1182/blood.V116.21.2798.2798

Published: 2010

Journal Articles

A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for Patients with Previously Untreated Multiple Myeloma (MM).

James R. Berenson, MD, Ori Yellin, MD, Ravi Patel, MD, Chien-Shing Chen, MD, Ralph Vincent Boccia, MD, Donald Colbourn, MD, Honghao (Hank) Yang, MD, PhD, Varun Gupta, MD, George F. Geils, Jr., MD, Youram Nassir, MD, Jacqueline Hilger, MS, Regina A. Swift

Blood (2009) 114 (22): 4936.

https://doi.org/10.1182/blood.V114.22.4936.4936

Published: 2009

Journal Articles

Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML

Jianbiao Zhou, Chonglei Bi, Jasinghe V. Janakakumara, Shaw-Cheng Liu, Wee-Joo Chng, Kian-Ghee Tay, Lai-Fong Poon, Zhigang Xie, Senthilnathan Palaniyandi, Hanry Yu, Keith B. Glaser, Daniel H. Albert, Steven K. Davidsen, Chien-Shing Chen

Blood (2009) 113 (17): 4052–4062.

https://doi.org/10.1182/blood-2008-05-156422

Published: 2009

Includes: Supplemental data

Journal Articles

Identification of Core Gene Signature Associated with Synergism Between ABT-869, a FLT3 Inhibitor and SAHA, a HDAC Inhibitor in AML with FLT3-ITD Mutation.

Jianbiao Zhou, MD, MS, Chonglei Bi, Bsc, Shaw-Cheng Liu, Wee-Joo Chng, MD, Kian-Ghee Tay, Bsc, Hanry Yu, Ph.D., Keith Glaser, Ph.D., Daniel Albert, PhD, BSc, Steven K Davidsen, Ph.D., Chien-Shing Chen, MD, PhD

Blood (2008) 112 (11): 1618.

https://doi.org/10.1182/blood.V112.11.1618.1618

Published: 2008

Journal Articles

Overactivation of STAT Pathways and Overexpression of Survivin Confer Resistance to FLT3 Inhibitors and Could Be Therapeutic Targets in AML.

Jianbiao Zhou, MD, MSc, Chonglei Bi, B.S., Lai Fong Poon, B.S., Viraj J. Janakakumara, B.S., Jiaying Khng, Hanry Yu, Ph.D., Keith B. Glaser, Ph.D., Daniel H. Albert, Ph.D., Davidsen K. Davidsen, Ph.D., Chien-Shing Chen, Ph.D.

Blood (2007) 110 (11): 2367.

https://doi.org/10.1182/blood.V110.11.2367.2367

Published: 2007

Journal Articles

SB939: A Potent and Orally Active HDAC Inhibitor for the Treatment of Hematological Malignancies.

Kanda Sangthongpitag, Walter Stunkel, Zahid Q. Bonday, Kee C. Goh, Xukun Wang, Xiaofeng Wu, Changyong Hu, Haishan Wang, Niefang Yu, Eric Sun, Michael Entzeroth, Ethirajulu Kantharaj, Chien-Shing Chen, Jeanette M. Wood

Blood (2007) 110 (11): 1603.

https://doi.org/10.1182/blood.V110.11.1603.1603

Published: 2007

Journal Articles

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study

Blood (2007) 110 (4): 1388–1396.

https://doi.org/10.1182/blood-2007-02-072389

Published: 2007

Journal Articles

Merit of Initiating Peripheral Blood Stem Cell (PBSC) Collections at Low Level of Circulating CD34+ Cells.

Ping Law, PhD, Lip Kun Tan, MD, Fathalha Yasir, BS, Teck Guan Soh, BS, Joanna K.Y. Mah, BS, Jenny Li, BS, Te Chih Liu, MD, Chien Shing Chen, MD, PhD

Blood (2005) 106 (11): 5262.

https://doi.org/10.1182/blood.V106.11.5262.5262

Published: 2005

Journal Articles

Genistein Promotes Apoptosis, Differentiation and Cell Cycle Arrest in All Trans Retinoic Acid (ATRA) Sensitive and Resistant Acute Promyelocytic Leukemia Cells.

Matiullah Khan, MBBS, Ph.D., Angela Ping Ping Ng, Msc, Shen Jing, MD, Chien-Shing Chen, MD, Ph.D., Shunsuke Ishii, Ph.D

Blood (2004) 104 (11): 2524.

https://doi.org/10.1182/blood.V104.11.2524.2524

Published: 2004

Journal Articles

Loss of heterozygosity in childhood de novo acute myelogenous leukemia

David A. Sweetser, Chien-Shing Chen, Adam A. Blomberg, David A. Flowers, Patricia C. Galipeau, Michael T. Barrett, Nyla A. Heerema, Jonathan Buckley, William G. Woods, Irwin D. Bernstein, Brian J. Reid

Blood (2001) 98 (4): 1188–1194.

https://doi.org/10.1182/blood.V98.4.1188

Published: 2001

NARROW

The New Landscape of Checkpoint Inhibitors in China

Novel AML-Associated Loss of Function Mutations in the B55 Alpha Subunit of PP2A Are Associated with Increased Phosphorylation and Activation of AKT and Enhanced Sensitivity to AKT Inhibitor Induced Cell Growth Arrest

High Transcription Levels Of S100A8 and S100A9 In Acute Myeloid Leukemia Are Predictors For Poor Overall Survival

IGFBP7 Gene Promoting Cell Proliferation in Acute Myeloid Leukemia Through Activation of AKT3 and CCND1

C3aR1 Contributed to Acute Myeloid Leukemia Acquired Resistance to ABT-737 and Involved In the Process of AML

Bortezomib In Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin Followed by Rituximab Maintenance In Patients with Relapsed or Refractory Follicular Lymphoma: Results of a Phase 2 Study.

A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for Patients with Previously Untreated Multiple Myeloma (MM).

Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML

Identification of Core Gene Signature Associated with Synergism Between ABT-869, a FLT3 Inhibitor and SAHA, a HDAC Inhibitor in AML with FLT3-ITD Mutation.

Overactivation of STAT Pathways and Overexpression of Survivin Confer Resistance to FLT3 Inhibitors and Could Be Therapeutic Targets in AML.

SB939: A Potent and Orally Active HDAC Inhibitor for the Treatment of Hematological Malignancies.

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study

Merit of Initiating Peripheral Blood Stem Cell (PBSC) Collections at Low Level of Circulating CD34+ Cells.

Genistein Promotes Apoptosis, Differentiation and Cell Cycle Arrest in All Trans Retinoic Acid (ATRA) Sensitive and Resistant Acute Promyelocytic Leukemia Cells.

Loss of heterozygosity in childhood de novo acute myelogenous leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only